๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Results for Becker in 2002: surge in turnover, drop in profits


Book ID
104405097
Publisher
Elsevier Science
Year
2003
Weight
30 KB
Volume
2003
Category
Article
ISSN
1364-5439

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


Favourable results for Henkel in 1Q 2002
๐Ÿ“‚ Article ๐Ÿ“… 2002 ๐Ÿ› Elsevier Science โš– 39 KB

The increase in the net loss primarily reflects clinical trial costs incurred for the company's lead product, Surfaxin, currently in three Phase III trials and one Phase II trial. Selected updates on the company's progress in 1Q 2002 are included in the report. Revenues from collaborative agreements